The Online Investor
Crinetics Pharmaceuticals Inc (CRNX)

Crinetics Pharmaceuticals is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Paltusotine is an oral selective nonpeptide somatostatin receptor type 2 agonists designed for the treatment of acromegaly and neuroendocrine tumors. CRN04777 is Co.'s investigational, oral, nonpeptide somatostatin receptor type 5 agonist designed for the treatment of congenital hyperinsulinism. CRN04894 is Co.'s investigational, oral, nonpeptide product candidate designed to antagonize adrenocorticotrophic hormone, or ACTH, intended for the treatment of diseases caused by excess ACTH.

CRNX SEC Filing Email Alerts Service
Company Name: 
Crinetics Pharmaceuticals Inc
Website: 
www.crinetics.com
Sector: 
Drugs & Pharmaceuticals
Number of ETFs Holding CRNX: 
30
Total Market Value Held by ETFs: 
$361.48M
Total Market Capitalization: 
$3.02B
% of Market Cap. Held by ETFs: 
11.98%
Quotes delayed 20 minutes

Email EnvelopeFree CRNX Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts

Strong Buy (3.85 out of 4)
74th percentile
(ranked higher than approx. 74% of all stocks covered)

Analysts' Target Price:
CRNX Stock Forecast

Based on Zacks ABR data;
powered by Xignite

Crinetics Pharmaceuticals Inc (CRNX) Page | The Online Investor Page | www.TheOnlineInvestor.com

Copyright © 1998 - 2024, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.